On January 16, 2024, Biora Therapeutics, Inc., a biotech company specializing in therapeutic delivery, announced its outlook for the year and detailed its anticipated milestones for 2024. The company, which is listed on the Nasdaq Global Market under the symbol BIOR, is focusing on the development of its NaviCap™ Targeted Oral Delivery Platform and BT-600 program for ulcerative colitis, as well as its BioJet™ Systemic Oral Delivery Platform. Biora Therapeutics aims to improve patient outcomes by enabling targeted delivery of therapeutics directly to the site of disease, which could be particularly beneficial for the 1.8 million patients in the United States suffering from inflammatory bowel disease (IBD). The company's CEO, Adi Mohanty, highlighted the progress made in 2023 and the transformation of the company...Show More

On January 16, 2024, Biora Therapeutics, Inc., a biotech company specializing in therapeutic delivery, announced its outlook for the year and detailed its anticipated milestones for 2024. The company, which is listed on the Nasdaq Global Market under the symbol BIOR, is focusing on the development of its NaviCap™ Targeted Oral Delivery Platform and BT-600 program for ulcerative colitis, as well as its BioJet™ Systemic Oral Delivery Platform. Biora Therapeutics aims to improve patient outcomes by enabling targeted delivery of therapeutics directly to the site of disease, which could be particularly beneficial for the 1.8 million patients in the United States suffering from inflammatory bowel disease (IBD). The company's CEO, Adi Mohanty, highlighted the progress made in 2023 and the transformation of the company, setting the stage for significant value inflection in the upcoming months. The company's phase 1 study for BT-600 is a major step in the development of the NaviCap™ platform, with initial data from the study expected in 2-3 months. Additionally, Biora Therapeutics is developing a study protocol for a potential phase 1B study in ulcerative colitis patients and plans a 56-day GLP tox study with BT-600 in the second half of 2024. The BioJet™ platform is showing promise in the oral delivery of large molecules and is progressing with pharmaceutical collaborations, with the anticipation of expanding these into development partnerships later in the year. The company's press release also contains forward-looking statements, which are subject to risks and uncertainties.